Viana M(1)(2)(3), Sances G(3), Terrazzino S(4), Zecca C(2)(5), Goadsby PJ(1)(6), Tassorelli C(3)(7). Author information:
(1)Headache Group, Department of Basic and Clinical Neurosciences, King's
College London, London, UK.
(2)Neurocenter of Southern Switzerland, Neurology clinic, Headache Center,
(3)Headache Science Center, IRCCS Mondino Foundation, Pavia, Italy.
(4)Department of Pharmaceutical Sciences, University of Piemonte Orientale,
(5)Faculty of biomedical Sciences, Università della Svizzera Italiana, Lugano,
(6)NIHR-Wellcome Trust Clinical Research Facility, King's College Hospital,
(7)Department of Brain and Behavioural Sciences, University of Pavia, Pavia,
BACKGROUND: Triptans, specific symptomatic medications for migraine, are not effective in a proportion of patients, or in all attacks, hence the importance of identifying predictors of response. Our aim was to investigate the association between the efficacy of oral frovatriptan 2.5 mg and clinical characteristics of migraine attacks. METHODS: We enrolled 29 consecutive patients affected by migraine without aura at the Headache Center of "Mondino" Institute of Pavia. Each patient was given a diary and asked to record prospectively the features of three consecutive migraine attacks while using frovatriptan. A generalized estimating equations approach was used to determine phenotypic features associated with the pain free response at 2 hours. RESULTS: Participants provided complete data for 85 attacks. Thirty of these (34%) patients reported being pain free 2 hours after taking frovatriptan 2.5 mg intake. Unilateral pain, presence of phonophobia, presence of one or more cranial autonomic symptoms and presence of one or more premonitory symptom were each associated with being pain free at 2 hours. CONCLUSIONS: The response to frovatriptan was associated with particular features of the migraine attack, either before or during the pain phase of attacks. The data support larger studies to explore detailed attack phenotyping, with particular attention to early signs, to enable individualized treatment in migraine.
Having over 250 Research scholars worldwide and more than 400 articles online with open access.